Financial goals


The company targets to achieve a turnover of 15.4 MSEK in 2022 and 60 MSEK in 2023.

Prostatype Genomics financial targets set forth above constitute forward-looking information and are based on a number of assumptions about the environment in which the Company operates, which may vary significantly and deteriorate over time from what Prostatype Genomics assessed when the financial targets were adopted. As a consequence, Prostatype Genomics’ ability to achieve the financial targets consists of uncertainties and contingencies, some of which are outside the Company’s control. There is no guarantee that Prostatype Genomics can achieve the financial targets or that Prostatype Genomics’ financial position or operating profit will not differ materially from the financial targets.